Evidence map›Paper›PMID 35204196›Full record

ArticleAntioxidants (Basel, Switzerland)2022

Androgen-Dependent Prostate Cancer Cells Reprogram Their Metabolic Signature upon GLUT1 Upregulation by Manganese Superoxide Dismutase.

Isabel Quiros-Gonzalez, Pedro Gonzalez-Menendez, Juan C Mayo, David Hevia, Francisco Artime-Naveda, Sheila Fernandez-Vega, Mario Fernandez-Fernandez, Pablo Rodriguez-Gonzalez, José I Garcia-Alonso, Rosa M Sainz

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. CSDE1 Drives Glycolysis and the Progression of Prostate Cancer Through RAC1-Dependent RAS/MAPK Activation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Insights into Manganese Superoxide Dismutase and Human Diseases.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Isabel Quiros-GonzalezDepartamento de Morfologia y Biologia Celular, Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), University of Oviedo, 33006 Oviedo, Spain.
Pedro Gonzalez-MenendezInstitute de Genetique Moleculaire de Montpellier, University of Montpellier, CNRS, 34293 Montpellier, France.ORCID 0000-0003-3114-6304
Juan C MayoDepartamento de Morfologia y Biologia Celular, Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), University of Oviedo, 33006 Oviedo, Spain.ORCID 0000-0002-0882-2047
David HeviaDepartamento de Morfologia y Biologia Celular, Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), University of Oviedo, 33006 Oviedo, Spain.
Francisco Artime-NavedaDepartamento de Morfologia y Biologia Celular, Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), University of Oviedo, 33006 Oviedo, Spain.
Sheila Fernandez-VegaDepartamento de Morfologia y Biologia Celular, Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), University of Oviedo, 33006 Oviedo, Spain.
Mario Fernandez-FernandezDepartamento de Quimica Fisica y Analítica, Universidad de Oviedo, Julián Clavería 8, 33006 Oviedo, Spain.
Pablo Rodriguez-GonzalezInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33001 Oviedo, Spain.ORCID 0000-0001-9317-8833
José I Garcia-AlonsoInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33001 Oviedo, Spain.ORCID 0000-0002-8356-3866
Rosa M SainzDepartamento de Morfologia y Biologia Celular, Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), University of Oviedo, 33006 Oviedo, Spain.ORCID 0000-0003-3048-5582
Universidad de Oviedo · ESCentre National de la Recherche Scientifique · FR

Funding

Gobierno del Principado de Asturias 2018/00076/032Gobierno del Principado de Asturias ACB17-38Ministry of Economy, Industry and Competitiveness MINECO-BFU2016-79139
6 · The paper itself

Abstract

Prostate cancer is the second leading cause of cancer in men across the globe. The prostate gland accounts for some unique glycolytic metabolic characteristics, which causes the metabolic features of prostate tumor initiation and progression to remain poorly characterized. The mitochondrial superoxide dismutase (SOD2) is one of the major redox metabolism regulators. This study points out SOD2 as one major regulator for both redox and glycolytic metabolism in prostate cancer. SOD2 overexpression increases glucose transporter GLUT-1 and glucose uptake. This is not an insulin-mediated effect and seems to be sex-dependent, being present in male mice only. This event concurs with a series of substantial metabolic rearrangements at cytoplasmic and mitochondrial level. A concomitant decrease in glycolytic and pentose phosphate activity, and an increase in electron transfer in the mitochondrial electronic chain, were observed. The Krebs Cycle is altered to produce amino-acid intermediates by decreasing succinate dehydrogenase. This in turn generates a 13-fold increase in the oncometabolite succinate. The protein energy sensor AMPK is decreased at basal and phosphorylated levels in response to glucose deprivation. Finally, preliminary results in prostate cancer patients indicate that glandular areas presenting high levels of SOD2 show a very strong correlation with GLUT-1 protein levels (R

Indexed as

GLUT-1metabolismprostate cancerredoxSDHSOD2

Identifiers

PMID35204196
PMCPMC8868133
OpenAlexW4210454811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.